Edoardo Campioli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edoardo Campioli has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Sirotti
General Surgery and Kidney Transplantation Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication - Andrea Collini
Renal Transplant Center, Siena University Hospital, Siena, Italy
1 shared publication - Andrea Costantino
Gastroenterology and Endoscopy Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
1 shared publication - Andrea Guarneri
Department of Clinical Sciences and Community Health (DISCCO) Università degli Studi di Milano Milan Italy
1 shared publication - Evaldo Favi
General Surgery and Kidney Transplantation Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication - Federico Ambrogi
Scientific Directorate, IRCCS Policlinico San Donato , San Donato Milanese, 20097, Milan
1 shared publication
Latest Publications
- Open Access
- 8 December 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15218
Human cytomegalovirus‐related gastrointestinal disease after kidney transplantation: A systematic review
Background: Human‐cytomegalovirus (hCMV) infection involving the gastrointestinal tract represents a leading cause of morbidity and mortality among kidney transplant (KT) recipients (KTRs). Signs and symptoms of the disease are extremely variable. Prompt anti‐viral therapy administration and immunosuppression modification are key factors for optimizing management. However, complex work‐up strategies are generally required to confirm the preliminary diagnosis. Unfortunately, solid evidence and guidelines on this specific topic are not available.We consequently aimed to summarize current knowledge on post‐KT hCMV‐related gastrointestinal disease (hCMV‐GID).Methods: We conducted a systematic review (PROSPERO ID: CRD42023399363) about hCMV‐GID in KTRs.Results: Our systematic review includes 52 case‐reports and ten case‐series, published between 1985 and 2022, collectively reporting 311 cases. The most frequently reported signs and symptoms of hCMV‐GID were abdominal pain, diarrhea, epigastric pain, vomiting, fever, and GI bleeding. Esophagogastroduodenoscopy and colonoscopy were the primary diagnostic techniques. In most cases, the preliminary diagnosis was confirmed by histology. Information on anti‐viral prophylaxis were extremely limited as much as data on induction or maintenance immunosuppression. Treatment included ganciclovir and/or valganciclovir administration. Immunosuppression modification mainly consisted of mycophenolate mofetil or calcineurin inhibitor minimization and withdrawal. In total, 21 deaths were recorded. Renal allograft‐related outcomes were described for 26 patients only. Specifically, reported events were acute kidney injury (n = 17), transplant failure (n = 5), allograft rejection (n = 4), and irreversible allograft dysfunction (n = 3).Conclusions: The development of local and national registries is strongly recommended to improve our understanding of hCMV‐GID. Future clinical guidelines should consider the implementation of dedicated diagnostic and treatment strategies.
- 8 December 2023
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15218
Open AccessHuman cytomegalovirus‐related gastrointestinal disease after kidney transplantation: A systematic review
Background: Human‐cytomegalovirus (hCMV) infection involving the gastrointestinal tract represents a leading cause of morbidity and mortality among kidney transplant (KT) recipients (KTRs). Signs and symptoms of the disease are extremely variable. Prompt anti‐viral therapy administration and immunosuppression modification are key factors for optimizing management. However, complex work‐up strategies are generally required to confirm the preliminary diagnosis. Unfortunately, solid evidence and guidelines on this specific topic are not available.We consequently aimed to summarize current knowledge on post‐KT hCMV‐related gastrointestinal disease (hCMV‐GID).Methods: We conducted a systematic review (PROSPERO ID: CRD42023399363) about hCMV‐GID in KTRs.Results: Our systematic review includes 52 case‐reports and ten case‐series, published between 1985 and 2022, collectively reporting 311 cases. The most frequently reported signs and symptoms of hCMV‐GID were abdominal pain, diarrhea, epigastric pain, vomiting, fever, and GI bleeding. Esophagogastroduodenoscopy and colonoscopy were the primary diagnostic techniques. In most cases, the preliminary diagnosis was confirmed by histology. Information on anti‐viral prophylaxis were extremely limited as much as data on induction or maintenance immunosuppression. Treatment included ganciclovir and/or valganciclovir administration. Immunosuppression modification mainly consisted of mycophenolate mofetil or calcineurin inhibitor minimization and withdrawal. In total, 21 deaths were recorded. Renal allograft‐related outcomes were described for 26 patients only. Specifically, reported events were acute kidney injury (n = 17), transplant failure (n = 5), allograft rejection (n = 4), and irreversible allograft dysfunction (n = 3).Conclusions: The development of local and national registries is strongly recommended to improve our understanding of hCMV‐GID. Future clinical guidelines should consider the implementation of dedicated diagnostic and treatment strategies.